Terms: = Prostate cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257
1165 results:
1. The Suppression of the Epithelial to Mesenchymal Transition in prostate cancer through the Targeting of MYO6 Using MiR-145-5p.
Armstrong L; Willoughby CE; McKenna DJ
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673886
[TBL] [Abstract] [Full Text] [Related]
2. Knockdown of growth differentiation factor-15 restrains prostate cancer through regulating MAPK/ERK signaling pathway.
Yang M; Guo M; Su C; Hao W; Xu Z
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):162-167. PubMed ID: 38650142
[TBL] [Abstract] [Full Text] [Related]
3. Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
Wu C; Zhu H; Zhang Y; Ding L; Wang J
PLoS One; 2024; 19(4):e0290753. PubMed ID: 38598542
[TBL] [Abstract] [Full Text] [Related]
4. Overexpression of REST Represses the Epithelial-Mesenchymal Transition Process and Decreases the Aggressiveness of prostate cancer Cells.
Indo S; Orellana-Serradell O; Torres MJ; Castellón EA; Contreras HR
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542313
[TBL] [Abstract] [Full Text] [Related]
5. Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway.
Zhang X; Li H; Wang Y; Zhao H; Wang Z; Chan FL
Cell Death Dis; 2024 Mar; 15(3):234. PubMed ID: 38531859
[TBL] [Abstract] [Full Text] [Related]
6. Targeting HOXA11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.
Zhang J; Li S; Zhang M; Wang Z; Xing Z
J Cell Mol Med; 2024 Apr; 28(8):e18227. PubMed ID: 38520207
[TBL] [Abstract] [Full Text] [Related]
7. Multifaceted impact of adipose conditioned media: Obesity-driven promotion of prostate cancer and cancer stem cell dynamics.
Erdogan S; Serttas R; Dibirdik I; Turkekul K
Cell Biochem Funct; 2024 Mar; 42(2):e3979. PubMed ID: 38481004
[TBL] [Abstract] [Full Text] [Related]
8. Investigation of in-vitro Anti-cancer and Apoptotic Potential of Garlic-Derived Nanovesicles against prostate and Cervical cancer Cell Lines.
Sharma V; Sinha ES; Singh J
Asian Pac J Cancer Prev; 2024 Feb; 25(2):575-585. PubMed ID: 38415544
[TBL] [Abstract] [Full Text] [Related]
9. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
10. Cationic solid lipid nanoparticles (SLN) complexed with plasmid DNA enhance prostate cancer cells (PC-3) migration.
Garcia-Fossa F; de Jesus MB
Nanotoxicology; 2024 Feb; 18(1):36-54. PubMed ID: 38300021
[TBL] [Abstract] [Full Text] [Related]
11. ZNF692 promotes cell proliferation, invasion and migration of human prostate cancer cells by targeting the emt signaling pathway.
Chen H; Li Y; Wu G; Zeng Q; Huang H; Zhang G
Eur J Med Res; 2024 Jan; 29(1):88. PubMed ID: 38291502
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions.
Mei S; Alchahin AM; Tsea I; Kfoury Y; Hirz T; Jeffries NE; Zhao T; Xu Y; Zhang H; Sarkar H; Wu S; Subtelny AO; Johnsen JI; Zhang Y; Salari K; Wu CL; Randolph MA; Scadden DT; Dahl DM; Shin J; Kharchenko PV; Saylor PJ; Sykes DB; Baryawno N
Genome Med; 2024 Jan; 16(1):1. PubMed ID: 38281962
[TBL] [Abstract] [Full Text] [Related]
13. Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer.
Said R; Hernández-Losa J; Moline T; de Haro RSL; Zouari S; Blel A; Rammeh S; Derouiche A; Ouerhani S
Mol Biol Rep; 2024 Jan; 51(1):226. PubMed ID: 38281235
[TBL] [Abstract] [Full Text] [Related]
14. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Li J; Hong Z; Zhang J; Zheng S; Wan F; Liu Z; Dai B
Oncogene; 2024 Mar; 43(10):744-757. PubMed ID: 38243079
[TBL] [Abstract] [Full Text] [Related]
15. Harnessing function of emt in cancer drug resistance: a metastasis regulator determines chemotherapy response.
Ebrahimi N; Manavi MS; Faghihkhorasani F; Fakhr SS; Baei FJ; Khorasani FF; Zare MM; Far NP; Rezaei-Tazangi F; Ren J; Reiter RJ; Nabavi N; Aref AR; Chen C; Ertas YN; Lu Q
Cancer Metastasis Rev; 2024 Mar; 43(1):457-479. PubMed ID: 38227149
[TBL] [Abstract] [Full Text] [Related]
16. circCPA4 induces malignant behaviors of prostate cancer via miR-491-5p/SHOC2 feedback loop.
Xu W; Zhong Z; Gu L; Xiao Y; Chen B; Hu W
Clinics (Sao Paulo); 2024; 79():100314. PubMed ID: 38219533
[TBL] [Abstract] [Full Text] [Related]
17. Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.
Ambrosini G; Cordani M; Zarrabi A; Alcon-Rodriguez S; Sainz RM; Velasco G; Gonzalez-Menendez P; Dando I
Cell Commun Signal; 2024 Jan; 22(1):36. PubMed ID: 38216942
[TBL] [Abstract] [Full Text] [Related]
18. Serine/threonine kinase 36 induced epithelial-mesenchymal transition promotes docetaxel resistance in prostate cancer.
He T; Li NX; Pan ZJ; Zou ZH; Chen JC; Yu SZ; Lv F; Xie QC; Zou J
Sci Rep; 2024 Jan; 14(1):729. PubMed ID: 38184689
[TBL] [Abstract] [Full Text] [Related]
19. Dampened Regulatory Circuitry of TEAD1/ITGA1/ITGA2 Promotes TGFβ1 Signaling to Orchestrate prostate cancer Progression.
Cruz SP; Zhang Q; Devarajan R; Paia C; Luo B; Zhang K; Koivusalo S; Qin L; Xia J; Ahtikoski A; Vaarala M; Wenta T; Wei GH; Manninen A
Adv Sci (Weinh); 2024 Mar; 11(11):e2305547. PubMed ID: 38169150
[TBL] [Abstract] [Full Text] [Related]
20. PrLZ regulates emt and invasion in prostate cancer via the TGF-β1/p-smad2/miR-200 family/ZEB1 axis.
Xie H; Chen J; Ma Z; Gao Y; Zeng J; Chen Y; Yang Z; Xu S
Prostate; 2024 Mar; 84(4):317-328. PubMed ID: 38145367
[TBL] [Abstract] [Full Text] [Related]
[Next]
